FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Opinion On Shares Of Semtech Corp.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We increase our 12-month target price to $140 from $100, on a higher revised P/E of about 48x our CY 2027 EPS of $2.90, which is above wireless peers and the range of analog peers to reflect our view of upside to consensus views and superior growth prospects over the next three years. We believe that SMTC is well positioned to capitalize on the AI infrastructure build-out, with data center revenue growing 58% in FY 26 and guided for over 50% in FY 27. The recent acquisition of HieFo Corporation, a manufacturer of Indium Phosphide lasers, is a pivotal move to vertically integrate and increase content in next-generation 1.6T and 3.2T optical modules, expanding the content opportunity from ~$8 in 800G modules to ~$80 in 3.2T modules. We are confident in SMTC's technology roadmap, highlighting imminent product ramps in Active Copper Cables and 1.6T optical solutions, which could drive $100M+ incremental revenue opportunity as hyperscalers transition to higher-speed architectures over the next two to three years.

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Healthpeak Properties, Inc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $2 to $21, reflecting a forward P/FFO of 12.0x our 2026 FFO estimate, a discount to DOC's three-year forward average (10.6x) as headwinds in Lab are likely to continue in 2026 mixed with capital recycling plans early in the year. We lower our 2026 FFO view by $0.02 to $1.75 and increase 2027's by $0.02 to $1.82. DOC successfully executed the IPO of Janus Living, which now trades at a premium multiple relative to DOC. We believe this will accelerate JAN's acquisition ability in the senior housing market. The most surprising note from management was that it sees the lab space likely to grow occupancy by the end of 2026. This is strong outperformance relative to the largest lab focused operator Alexandria Real Estate Equities, with DOC guiding for a 100-bp improvement this year. Boston continues to be the market with the largest oversupply of lab space, but the West Cambridge location specifically is seeing strong demand currently.

$DOC
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of T. Rowe Price Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $10 to $110, valuing TROW shares at 11.3x our 2026 EPS estimate of $9.76 (lowered by $0.34) and at 11x our 2027 EPs estimate of $10.02 (cut by $0.23), versus their one-year average forward multiple of 10.6x and a peer average of 16x, which includes firms with wider margins and better organic growth prospects. TROW posted Q1 adjusted EPS of $2.52 versus $2.23 in the prior year, beating our $2.50 estimate and the $2.35 consensus estimate. However, results were overshadowed by continued structural headwinds. Net outflows of $13.7B were dominated by $22.6B in outflows from equity funds, reflecting the ongoing secular shift away from active equity strategies. AUM declined $65.9B to $1.7T due to outflows and $52.2B in market depreciation. Meanwhile, fee rate compression continued, with the rate falling to 38.4 bps from 40.0 bps in the prior year. Despite TROW's discounted valuation to peers, we believe the shares lack a near-term catalyst.

$TROW
Research

Research Alert: Otex Delivers Q3 Beats; Enterprise Cloud Bookings Accelerates.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:OTEX reported Q3 revenue of $1.283B, growing 2.2% Y/Y and beating consensus by $10M, while non-GAAP EPS of $1.01 exceeded estimates by $0.09 and grew 23.2% Y/Y. Cloud revenue rose 6.6% to $493M with enterprise cloud bookings accelerating 29.6% to $196M, marking the 21st consecutive quarter of cloud organic growth. The enterprise cloud bookings acceleration suggests OTEX's "Enterprise Information Management for AI" positioning is gaining customer traction amid the enterprise AI transition. The completion of CEO transition with Ayman Antoun's April 2026 start removes a key business overhang for the stock. Adjusted EBITDA margin expanded to 34.1% from 31.5% prior year, demonstrating strong operational leverage despite continued AI and cloud investments. We believe the company's disciplined cost management supports margin expansion. The company returned $313M to shareholders including $247M in repurchases, though free cash flow declined 18.4% to $305M on higher capex and working capital changes.

$OTEX